His first contract was an advertisement for cereal. He later gained recognition for his role as Noah Jackson in The Latest Buzz from 2007 to 2011. He acted alongside Munro Chambers and Demetrius ...
Uniqure NV is regrouping after a surprise switcheroo by the havoc-beset U.S. FDA regarding phase I/II studies with AMT-130 vs. external control in Huntington’s disease (HD) – news of which pushed down ...
AI-powered vector design and preclinical validation mark the first step in a multi-phase program aimed at accelerating the path from discovery to clinical assessment in Alzheimer's disease. AUSTIN, TX ...
Shortly after taking the reins at BioMarin, CEO Alexander Hardy laid out three paths the company could take for its struggling hemophilia A gene therapy, Roctavian. A year after opting to shrink the ...
BioMarin no longer expects to hit its $4 billion revenue target by 2027, citing various market factors such as impending competition for achondroplasia therapy Voxzogo and the divestment of the gene ...
Oct 27 (Reuters) - BioMarin Pharmaceutical (BMRN.O), opens new tab said on Monday it plans to divest its gene therapy, a product once expected to be a blockbuster treatment for a type of rare bleeding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback